JP7204729B2 - 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 - Google Patents

新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 Download PDF

Info

Publication number
JP7204729B2
JP7204729B2 JP2020500863A JP2020500863A JP7204729B2 JP 7204729 B2 JP7204729 B2 JP 7204729B2 JP 2020500863 A JP2020500863 A JP 2020500863A JP 2020500863 A JP2020500863 A JP 2020500863A JP 7204729 B2 JP7204729 B2 JP 7204729B2
Authority
JP
Japan
Prior art keywords
amino acid
mutants
mutant
acid residues
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020500863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021507676A (ja
Inventor
スンジェ パク
ヘシン チョン
スンジュ イ
ソナ ユ
ヒョンナム ソン
チャンウ イ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alteogen Inc
Original Assignee
Alteogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alteogen Inc filed Critical Alteogen Inc
Publication of JP2021507676A publication Critical patent/JP2021507676A/ja
Priority to JP2022211105A priority Critical patent/JP2023052142A/ja
Application granted granted Critical
Publication of JP7204729B2 publication Critical patent/JP7204729B2/ja
Priority to JP2024159834A priority patent/JP2025004002A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020500863A 2018-07-25 2019-07-25 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 Active JP7204729B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022211105A JP2023052142A (ja) 2018-07-25 2022-12-28 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物
JP2024159834A JP2025004002A (ja) 2018-07-25 2024-09-17 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2018-0086308 2018-07-25
KR20180086308 2018-07-25
KR20190029758 2019-03-15
KR10-2019-0029758 2019-03-15
PCT/KR2019/009215 WO2020022791A1 (ko) 2018-07-25 2019-07-25 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022211105A Division JP2023052142A (ja) 2018-07-25 2022-12-28 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物

Publications (2)

Publication Number Publication Date
JP2021507676A JP2021507676A (ja) 2021-02-25
JP7204729B2 true JP7204729B2 (ja) 2023-01-16

Family

ID=69182377

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020500863A Active JP7204729B2 (ja) 2018-07-25 2019-07-25 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物
JP2022211105A Pending JP2023052142A (ja) 2018-07-25 2022-12-28 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物
JP2024159834A Pending JP2025004002A (ja) 2018-07-25 2024-09-17 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022211105A Pending JP2023052142A (ja) 2018-07-25 2022-12-28 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物
JP2024159834A Pending JP2025004002A (ja) 2018-07-25 2024-09-17 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物

Country Status (11)

Country Link
US (2) US12371683B2 (enExample)
EP (1) EP3636752A4 (enExample)
JP (3) JP7204729B2 (enExample)
KR (3) KR102151388B1 (enExample)
CN (5) CN111971387A (enExample)
AU (2) AU2019311658B2 (enExample)
BR (1) BR112020019041A2 (enExample)
CA (1) CA3093885A1 (enExample)
MX (1) MX2020009824A (enExample)
RU (1) RU2766680C1 (enExample)
WO (1) WO2020022791A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2517145C (en) 2003-03-05 2017-08-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
BR112014016195A2 (pt) 2011-12-30 2020-10-27 Halozyme, Inc. variantes de polipeptídio ph20, formulações e usos das mesmas
JP7204729B2 (ja) 2018-07-25 2023-01-16 アルテオゼン インコーポレイテッド 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物
EP3876990A4 (en) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
CR20210489A (es) * 2019-03-25 2021-12-07 Alteogen Inc Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa ph20 y un medicamento
CN113840921A (zh) 2020-01-23 2021-12-24 阿特根公司 具有改善的稳定性的新玻尿酸酶变体及含有其的药物组合物
CN115776909A (zh) 2020-07-17 2023-03-10 美国杰龙生物医药公司 皮下端粒酶抑制剂组合物及其使用方法
CN120738156A (zh) * 2020-08-07 2025-10-03 阿特根公司 制备重组玻尿酸酶的方法
EP4217394A1 (en) * 2020-09-24 2023-08-02 Merck Sharp & Dohme LLC Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof
US20220233689A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Methods of treating tumors
RS66849B1 (sr) 2020-12-28 2025-06-30 Bristol Myers Squibb Co Kompozicije antitela i postupci njihove upotrebe
TW202305009A (zh) 2021-04-08 2023-02-01 美商默沙東有限責任公司 以皮下投予抗pd1抗體治療癌症之方法
CN115671267A (zh) 2021-07-23 2023-02-03 上海宝济药业有限公司 一种皮下抗生素药物组合物
EP4380618A2 (en) 2021-08-02 2024-06-12 argenx BV Subcutaneous unit dosage forms
EP4401758A1 (en) 2021-09-14 2024-07-24 Takeda Pharmaceutical Company Limited Facilitated delivery of concentrated antibody formulations using hyaluronidase
AU2022376750A1 (en) * 2021-10-29 2024-05-16 Alteogen Inc. Pharmaceutical composition comprising human hyaluronidase ph20 and drug
EP4469586A1 (en) 2022-03-01 2024-12-04 Exuma Biotech Corp. Viral particles with membrane-bound hyaluronidase
CN114573715A (zh) * 2022-03-14 2022-06-03 江苏雅酶医药科技有限公司 一种重组长效人透明质酸酶及其生产方法和应用
KR20230150203A (ko) 2022-04-20 2023-10-30 주식회사 알토스바이오로직스 오크렐리주맙(Ocrelizumab)을 포함하는 약학적 조성물과 그의 용도
AU2023281061A1 (en) 2022-06-02 2024-12-05 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
KR102774438B1 (ko) * 2022-06-08 2025-02-27 (주)한국비엠아이 히알루로니다제 폴리펩티드 및 이의 용도
CA3240340A1 (en) 2022-06-22 2023-12-28 Soon Jae Park N-terminal and/or c-terminal cleaved soluble ph20 polypeptide and use thereof
US20250345403A1 (en) * 2022-06-29 2025-11-13 Odysgen Inc. Hyaluronidase hyal1 variant exhibiting activity in neutral ph
KR102621518B1 (ko) * 2022-06-29 2024-01-10 주식회사 오디스젠 중성 pH에서 활성을 나타내는 히알루로니다제 Hyal1변이체
EP4562049A1 (en) * 2022-07-28 2025-06-04 Merck Sharp & Dohme LLC Pharmaceutical compositions of programmed death receptor 1 (pd-1) antibodies and rhuph20 or variants or fragments thereof
WO2024025986A1 (en) * 2022-07-28 2024-02-01 Merck Sharp & Dohme Llc Pharmaceutical compositions of programmed death receptor 1 (pd-1) antibodies and ph20 variants or fragments thereof
KR20240038901A (ko) * 2022-09-16 2024-03-26 (주)피앤피바이오팜 신규한 히알루로니다제 ph-20 변이체 및 그 용도
WO2024138188A1 (en) 2022-12-22 2024-06-27 Halozyme, Inc. Hyaluronidase enzyme formulations for high volume administration
CN120936711A (zh) * 2023-03-23 2025-11-11 阿特根公司 新型透明质酸酶变体及包括其的药物组合物
KR20250086876A (ko) * 2023-12-06 2025-06-16 (주)한국비엠아이 히알루로니다제 폴리펩티드와 약물을 포함하는 피하투여용 조성물
WO2025136032A1 (ko) * 2023-12-21 2025-06-26 주식회사 오디스젠 개선된 특성을 갖는 히알루로니다제 hyal2 변이체
KR102875495B1 (ko) * 2023-12-28 2025-10-27 주식회사 오디스젠 히알루로니다제 Hyal1 변이체

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515521A (ja) 2005-11-10 2009-04-16 レセプター バイオロジックス， インコーポレイテッド レセプターアイソフォームおよびリガンドアイソフォームの産生のための方法
WO2015003167A1 (en) 2013-07-03 2015-01-08 Halozyme, Inc. Thermally stable ph20 hyaluronidase variants and uses thereof
WO2016033555A1 (en) 2014-08-28 2016-03-03 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721348A (en) 1990-12-14 1998-02-24 University Of Connecticut DNA encoding PH-20 proteins
US5958750A (en) 1996-07-03 1999-09-28 Inctye Pharmaceuticals, Inc. Human hyaluronidase
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CA2517145C (en) * 2003-03-05 2017-08-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20090123367A1 (en) 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
WO2009037566A2 (en) 2007-06-19 2009-03-26 Uvarkina Tamara P Hyaluronidase and method of use thereof
ITMI20072225A1 (it) 2007-11-23 2009-05-24 Luso Farmaco Inst "composizioni farmaceutiche a base di antagonisti della bradichinina ed acido ialuronico e loro uso"
CN106906196A (zh) 2008-03-06 2017-06-30 哈洛齐梅公司 可溶性透明质酸酶的大规模生产
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
JP2011519361A (ja) * 2008-04-14 2011-07-07 ハロザイム インコーポレイテッド 修飾されたヒアルロニダーゼおよびヒアルロナン関連疾患および状態の治療における使用
ES2573462T3 (es) 2008-12-09 2016-06-08 Halozyme, Inc. Polipéptidos de PH20 soluble extendida y usos de los mismos
ES2724588T3 (es) 2008-12-09 2019-09-12 Halozyme Inc Polipéptidos de PH20 soluble extendida y usos de los mismos
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
US20100305500A1 (en) 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US9084743B2 (en) 2009-09-17 2015-07-21 Baxter International Inc. Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
US9220776B2 (en) 2011-03-31 2015-12-29 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
KR20140043438A (ko) 2011-06-17 2014-04-09 할로자임, 아이엔씨 히알루로난 분해 효소의 안정한 제형
BR112014016195A2 (pt) * 2011-12-30 2020-10-27 Halozyme, Inc. variantes de polipeptídio ph20, formulações e usos das mesmas
CN103173474B (zh) 2013-03-27 2014-08-27 广州白云山拜迪生物医药有限公司 一种用于cho细胞表达可溶性重组人透明质酸酶ph20的基因序列
JP6357363B2 (ja) 2013-06-26 2018-07-11 株式会社半導体エネルギー研究所 記憶装置
WO2015071366A1 (en) 2013-11-13 2015-05-21 Tillotts Pharma Ag Multi-particulate drug delivery system
KR102630750B1 (ko) 2013-12-17 2024-01-30 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
US20170218382A1 (en) 2014-07-31 2017-08-03 National University Corporation Kobe University Secretion Signal Peptide, And Protein Secretory Production And Cell Surface Display Using Said Secretion Signal Peptide
EP3207130B1 (en) 2014-10-14 2019-08-07 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
CN104745553B (zh) 2015-03-27 2017-11-28 杭州北斗生物技术有限公司 重组人透明质酸酶及其制备方法和采用聚乙二醇共价修饰的化合物和方法
CA2896038C (en) 2015-07-03 2022-08-09 Glycobiosciences Inc. Polymer matrix compositions comprising a high concentration of bio-fermented sodium hyaluronate and uses thereof
US9995753B2 (en) 2015-09-25 2018-06-12 Merck Sharp & Dohme Corp. Anti-pembrolizumab antibodies
PL3827845T3 (pl) 2015-11-03 2022-07-11 Janssen Biotech, Inc. Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania
AR107483A1 (es) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
CN105567606B (zh) 2016-03-02 2019-03-19 青岛海洋生物医药研究院股份有限公司 一种球形节杆菌及其产生的透明质酸酶
WO2018102372A1 (en) 2016-11-30 2018-06-07 Memorial Sloan Kettering Cancer Center Inhibitor-functionalized ultrasmall nanoparticles and methods thereof
KR20230144110A (ko) 2017-03-02 2023-10-13 제넨테크, 인크. Her2-양성 유방암 어쥬번트 치료
KR20250036268A (ko) 2017-03-31 2025-03-13 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
BR112019021847A2 (pt) 2017-05-30 2020-06-02 Bristol-Myers Squibb Company Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
JP7204729B2 (ja) 2018-07-25 2023-01-16 アルテオゼン インコーポレイテッド 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物
BR112021016398A2 (pt) 2019-02-22 2021-11-23 Memorial Sloan Kettering Cancer Center Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer
CR20210489A (es) 2019-03-25 2021-12-07 Alteogen Inc Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa ph20 y un medicamento
JP2020197994A (ja) 2019-06-04 2020-12-10 東芝テック株式会社 情報処理装置及びその制御プログラム
CN113840921A (zh) 2020-01-23 2021-12-24 阿特根公司 具有改善的稳定性的新玻尿酸酶变体及含有其的药物组合物
CN120738156A (zh) 2020-08-07 2025-10-03 阿特根公司 制备重组玻尿酸酶的方法
EP4217394A1 (en) 2020-09-24 2023-08-02 Merck Sharp & Dohme LLC Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof
AU2022376750A1 (en) 2021-10-29 2024-05-16 Alteogen Inc. Pharmaceutical composition comprising human hyaluronidase ph20 and drug

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515521A (ja) 2005-11-10 2009-04-16 レセプター バイオロジックス， インコーポレイテッド レセプターアイソフォームおよびリガンドアイソフォームの産生のための方法
WO2015003167A1 (en) 2013-07-03 2015-01-08 Halozyme, Inc. Thermally stable ph20 hyaluronidase variants and uses thereof
WO2016033555A1 (en) 2014-08-28 2016-03-03 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor

Also Published As

Publication number Publication date
EP3636752A4 (en) 2021-04-28
AU2023200324B2 (en) 2025-09-04
AU2019311658A8 (en) 2021-03-25
CN118853631A (zh) 2024-10-29
AU2023200324A1 (en) 2023-03-02
KR102151388B1 (ko) 2020-09-04
CN118773171A (zh) 2024-10-15
JP2023052142A (ja) 2023-04-11
AU2023200324B9 (en) 2025-12-04
AU2019311658B2 (en) 2022-10-20
US20210155913A1 (en) 2021-05-27
AU2019311658A1 (en) 2021-02-11
WO2020022791A1 (ko) 2020-01-30
US20250368976A1 (en) 2025-12-04
CA3093885A1 (en) 2020-01-30
BR112020019041A2 (pt) 2021-02-09
EP3636752A1 (en) 2020-04-15
US12371683B2 (en) 2025-07-29
KR20250021616A (ko) 2025-02-13
CN118792283A (zh) 2024-10-18
KR20210023798A (ko) 2021-03-04
MX2020009824A (es) 2021-01-15
RU2766680C1 (ru) 2022-03-15
JP2021507676A (ja) 2021-02-25
CN111971387A (zh) 2020-11-20
CN118755703A (zh) 2024-10-11
JP2025004002A (ja) 2025-01-14
KR20200017538A (ko) 2020-02-18

Similar Documents

Publication Publication Date Title
JP7204729B2 (ja) 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物
KR102801434B1 (ko) 안정성이 향상된 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물
KR20240110541A (ko) N-말단 및/또는 c-말단이 절단된 가용성 ph20 폴리펩티드 및 이의 용도
KR20250162568A (ko) 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물
RU2811464C2 (ru) Новые варианты гиалуронидазы с улучшенной стабильностью и содержащая их фармацевтическая композиция

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220816

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221228

R150 Certificate of patent or registration of utility model

Ref document number: 7204729

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250